sTWEAK在上皮性卵巢癌患者血清中的表达及其意义

目的:检测卵巢上皮性癌(EOC)患者外周血可溶性肿瘤坏死因子样凋亡微弱诱导剂(sTWEAK)的表达水平,并分析其临床意义。方法:选取2010年1月至2014年2月在上海交通大学附属仁济医院住院行手术的上皮性卵巢癌(EOC)患者和良性上皮性卵巢肿瘤患者共43例,采用ELISA法检测外周血血清中sTWEAK的表达水平。结果:(1)与良性上皮性卵巢肿瘤组相比,EOC组的sTWEAK的表达水平明显升高(P0.05)。两组患者中sTWEAK的表达与CA125呈正相关(r=0.42,P0.05),其中CA125500U/ml者的sTWEAK表达水平明显低于CA125500U/ml者(P0.05)。(2)EOC患者血清中,sTWEAK的表达水平与其临床分期、病理分级、组织类型以及腹水有无肿瘤细胞均无相关性(P0.05)。(3)EOC组中,CA125500U/ml者行满意肿瘤细胞减灭术的比例显著高于CA125500U/ml者(P0.05)。结论:sTWEAK虽不能反映EOC患者的肿瘤进展,但其与EOC的发生密切相关,sTWEAK可能成为判断卵巢肿瘤良恶性的新型血清学标记,在EOC诊断及预后预测中具有一定的应用前景。

Serum sTWEAK expression and its clinical significance in epithelial ovarian cancer pa-tients

Objective：To explore the expression level and clinical implications of ser-um soluble tumor necrosis factor---like weak inducer of apoptosis（ sTWEAK） in epithelial o-varian cancer patients. Method：20 patients with epithelial ovarian cancer （ EOC group） and 23 patients with benign epithelial ovarian tumor （ BOT group） were selected from Renji Hospital, School of Medicine,Shanghai Jiaotong University. These patients were admitted to the hospital during the period from Jan. 2010 to Feb. 2014. The levels of serum sTWEAK were detected by ELISA. Results：（1） Compared to the BOT group,the expression levels of sTWEAK were sig-nificantly increased in the EOC group （P〈0. 05）. In both groups,the expression levels of sTWEAK were positively correlated with serum CA125 levels （ r=0 . 42 , P〈0 . 05 ） . Further-more,compared to patients with a CA125〉500U/ml,the expression levels of sTWEAK were sig-nificantly decreased in patients with a CA125〈500 U/ml （ P〈0 . 05 ） . In peripheral serum of the EOC group,the expression levels of sTWEAK were not correlated to clinical stages,histological grade,pathological types and ascites presence of tumor cells（P〉0. 05）. （3）In EOC group,the proportion of optimal primary cytoreduction in patients with a CA125〈500 U/ml is significantly higher than that in patients with a CA125〉500 U/ml （ P〈0 . 05 ） . Conclusions：Serum sTWEAK levels were closely correlated with the pathogenesis of EOC. sTWEAK might be used as a new serum marker for diagnosis and prognosis in EOC.